Institutional shares held 39.1 Million
845K calls
1.23M puts
Total value of holdings $4.46B
$96.3M calls
$141M puts
Market Cap $27.7B
242,684,992 Shares Out.
Institutional ownership 16.13%
# of Institutions 327


Latest Institutional Activity in BNTX

Top Purchases

Q3 2024
New York State Common Retirement Fund Shares Held: 218K ($24.9M)
Q3 2024
Abrdn PLC Shares Held: 226K ($25.8M)
Q3 2024
Lodestone Wealth Management LLC Shares Held: 70.5K ($8.04M)
Q3 2024
Deka Bank Deutsche Girozentrale Shares Held: 481K ($54.9M)
Q3 2024
International Assets Investment Management, LLC Shares Held: 17.9K ($2.04M)

Top Sells

Q3 2024
Sg Americas Securities, LLC Shares Held: 8.1K ($923K)
Q3 2024
Vontobel Holding Ltd. Shares Held: 17.2K ($1.96M)
Q3 2024
Van Eck Associates Corp Shares Held: 94.7K ($10.8M)
Q3 2024
Robeco Institutional Asset Management B.V. Shares Held: 115K ($13.1M)
Q3 2024
Us Bancorp \De\ Shares Held: 4.68K ($533K)

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.


Insider Transactions at BNTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on BNTX

Follow BioNTech SE and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BNTX shares.

Notify only if

Insider Trading

Get notified when an Bio N Tech Se insider buys or sells BNTX shares.

Notify only if

News

Receive news related to BioNTech SE

Track Activities on BNTX